Corona Remedies Limited has notified the stock exchanges of its officials' scheduled participation in two investor conferences to be held in Mumbai on May 26 and May 27, 2026. The intimation has been made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Upcoming Investor Conference Schedule

The company's officials will attend both events in-person, engaging in Group and 1x1 meetings with analysts and investors. The following table outlines the details of the scheduled conferences:

Disclosure and Compliance

Corona Remedies has clarified that all discussions during both conferences will be based solely on publicly available information. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be discussed at either event. The company has also noted that changes in the above schedule may occur due to exigencies on the part of the host or the company.

This intimation has additionally been made available on the company's official website at www.coronaremedies.com . The disclosure was signed by Chetna Dharajiya, Company Secretary and Compliance Officer, on May 19, 2026.

CORONA Remedies Limited reported its audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026. The Board of Directors, at its meeting held on May 11, 2026, considered and approved the results. The company delivered robust performance across revenue and profitability metrics, driven by brand-building initiatives and operational efficiencies. The Board recommended a final dividend of ₹10 per equity share for FY26, with the record date fixed as Friday, June 19, 2026. Additionally, the Board approved the appointment of M/s. Walker Chandio & Co LLP as the Statutory Auditor for a period of five years.

Standalone Financial Performance

On a standalone basis, CORONA Remedies posted strong growth for FY26. Revenue from operations grew 17.3% year-on-year to ₹1,403.18 Crores from ₹1,196.42 Crores in FY25. Net profit after tax for FY26 was ₹184.85 Crores, up from ₹149.05 Crores in FY25. The company reported an exceptional item of ₹19.10 Crores (post-tax ₹14.29 Crores) in FY26, representing the statutory impact of the new Labour Codes notified by the Government of India. The table below summarises the standalone financial performance across Q4 FY26 and the full year:

Consolidated Financial Performance

On a consolidated basis, the company reported revenue from operations of ₹1,403.2 Crores for FY26 and a reported net profit after tax of ₹185.1 Crores. Adjusted for the one-time statutory impact of new Labour Codes of ₹19.1 Crores (post-tax ₹14.3 Crores), the adjusted PAT stood at ₹199.4 Crores, reflecting a 33.4% year-on-year growth. Consolidated total income for FY26 stood at ₹1,413.83 Crores versus ₹1,202.35 Crores in FY25. The consolidated financial highlights are presented below:

Key Highlights

The Board recommended a final dividend of ₹10/- per equity share for FY26. The record date is fixed as Friday, June 19, 2026. The company highlighted strategic milestones, including the acquisition of WOKADINE and 7 brands from Bayer Zydus Pharma. It received EAEU-GMP certification, enabling entry into markets including Russia and Kazakhstan. CORONA Remedies improved its industry ranking to 27th in India from 32nd.